



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Jiri Zemlicka, *et al.*

Serial No.: 10,047,202

Filed: January 14, 2002

For: 2-HYDROXYMETHYLCYCLOPROPYLI-
DENEMETHYLPURINES AND -PYRIMIDINES AS
ANTIVIRAL AGENTS

Attorney Docket No.: WSV-374CPCN

Group Art Unit: 1624

Examiner: M. L. Berch

DEC 02 2002

TECH CENTER 1600/2900

RECEIVED

3B
PS

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Nov. 20, 2002
Date of Signature and Mail Deposit

By:

DeAnn F. Smith
DeAnn F. Smith, Esq.
Reg. No. 36,683
Attorney for Applicants

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action mailed on October 1, 2002 (paper number 6). A separate request for a one-month extension of time up to December 1, 2002, is filed simultaneously herewith.

Please amend the application as follows:

In the claims:

Please amend claim 33 as follows:

pink
C1
BI
33. (Amended) An antiviral compound selected from the group consisting of methyl phenyl-phosphoro-L-alaninate of syn - N⁹ - (2 - hydroxymethylcyclopropylidenemethyl) adenine, methyl phenyl-phosphoro-L-alaninate of anti-N²-(2-hydroxymethylcyclopropylidenemethyl) adenine and pharmaceutically acceptable salts, and prodrugs, thereof.